UroGen Pharma (URGN) EBT Margin (2017 - 2026)
UroGen Pharma (URGN) posted quarterly EBT Margin of 55.63% for Q1 2026, up 15891.0% year-on-year from N/an in Q1 2025, and up 20.99% on a QoQ basis from 70.4% in Q4 2025.
UroGen Pharma (URGN) EBT Margin (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has reported EBT Margin for 10 consecutive years, with 55.63% the latest figure, recorded in Q1 2026.
- Quarterly EBT Margin rose 15891.0% year-over-year to 55.63% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98.45% (up 4878.0% YoY) and the FY2025 annual result came in at 139.74%, down 252.0% from the prior year.
- EBT Margin climbed to 55.63% in Q1 2026 per URGN's latest filing, from 70.4% in the prior quarter.
- Over the last five years, EBT Margin for URGN reached as high as 55.63% in Q1 2026 and fell as low as 214.53% in Q1 2025.
- A 5-year average of 140.92% and a median of 152.71% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2025 — EBT Margin plunged 4933 bps — and 2026, when it jumped 15891 bps.
- Year by year, EBT Margin stood at 155.76% in 2022, then soared by 40 bps to 94.19% in 2023, then tumbled by 51 bps to 141.92% in 2024, then jumped by 50 bps to 70.4% in 2025, then grew by 21 bps to 55.63% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 55.63%, 70.4%, and 125.18% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn | -55.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.63% |
| Dec 31, 2025 | -70.40% |
| Sep 30, 2025 | -125.18% |
| Jun 30, 2025 | -202.04% |
| Mar 31, 2025 | -214.53% |
| Dec 31, 2024 | -141.92% |
| Sep 30, 2024 | -93.56% |
| Jun 30, 2024 | -152.71% |
| Mar 31, 2024 | -171.62% |
| Dec 31, 2023 | -94.19% |
| Sep 30, 2023 | -104.97% |
| Jun 30, 2023 | -113.92% |
| Mar 31, 2023 | -175.62% |
| Dec 31, 2022 | -155.76% |
| Sep 30, 2022 | -156.07% |
| Jun 30, 2022 | -160.56% |
| Mar 31, 2022 | -206.92% |
| Dec 31, 2021 | -168.88% |
| Sep 30, 2021 | -266.15% |
| Jun 30, 2021 | -198.82% |